SOHO 2020 | Next questions in CAR-based therapies
John DiPersio, MD, PhD, of Washington University, St. Louis, MO, outlines the future of CAR-based therapies and highlights how unlike small-molecule agents, CAR-based treatments can be developed and tested by individual labs to modify and improve efficacy. Prof. DiPersio also discusses approaches to improve the efficacy of CAR T-cells including generating modified cells that can target multiple antigens as well as improving the in vivo persistence of CAR T-cells within patients. Lastly, Prof. DiPersio provides an overview of other effector cells evaluated for CAR use, including emerging NK cell therapies, iNK T-cells, activated NK cells, and macrophage based therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
